Personal information
No personal information available
Biography
I completed my B.Sc. with majors in Biochemistry and Organic Chemistry and subsequently my M.Sc. in Clinical Biochemistry at the University of Western Australia, before later completing my Ph.D. in the Faculty of Medicine at The University of Sydney. I have worked extensively in biomedical research and have experience in the areas of neuropharmacology and behavioural pharmacology, bioanalysis and assay validation, pharmacokinetics and pharmacodynamics, drug metabolism, and drug development. I have worked extensively with laboratory rodent behavioural and experimental models, as well as with LC-MS and HPLC, and I also have experience with histology and immunostaining procedures for microscopy. Additionally, I have experience with the use of WinNonlin® software for the analysis of pharmacokinetic data, scientific writing for commercial research projects, and working in a Quality System environment.
Earlier work has included studies of the pharmacokinetics, pharmacodynamics, and biodistribution of thiopentone enantiomers, in addition to studies of the pharmacokinetics and biodistribution of ketamine enantiomers and the pharmacokinetic-pharmacodynamic interaction of alfentanil with ketamine. Other projects have included the pharmacokinetics of morphine and oxycodone and their respective primary metabolites; development of LC-MS assays for angiotensin II type 2 receptor antagonists; and evaluation and validation of 2 transgenic mouse models of Alzheimer’s disease. More recently, I have worked on a project investigating the use of novel complement pathway inhibitors for the treatment of traumatic brain injury. Currently, I work on a project investigating a novel treatment for amyotrophic lateral sclerosis (ALS), in 2 transgenic mouse models of ALS. To date I have 34 publications in international peer reviewed journals.